Results 191 to 200 of about 21,353 (254)

Response to FDA Adverse Event Reporting System (FAERS) Essentials: A Reflection on Study Conception. [PDF]

Clin Pharmacol Ther
Reyes M, Potter E, Dal Pan G.
europepmc   +1 more source

FDA Adverse Event Reporting System (FAERS) Essentials: A Guide to Understanding, Applying, and Interpreting Adverse Event Data Reported to FAERS. [PDF]

Clin Pharmacol Ther
Potter E, Reyes M, Naples J, Dal Pan G.
europepmc   +1 more source

Monthly buprenorphine depot injection (SUBLOCADE®) for opioid use disorder during pregnancy. [PDF]

Am J Addict
Ramage M, Bishop B, Mangano V, Mankabady B.   +3 more
europepmc   +1 more source

Postmarketing adverse events of efgartigimod alfa: a real-world pharmacovigilance study based on the FAERS database. [PDF]

BMJ Open
Ju Y, Qin X.
europepmc   +1 more source

Massive Submacular Hemorrhage Following Intravitreal Faricimab Injection for Neovascular Age-Related Macular Degeneration. [PDF]

Cureus
Kaganovski A, Rostomian N, Shrier E.
europepmc   +1 more source

Safety of Risdiplam in Japanese Patients with Spinal Muscular Atrophy: A 12‑Month Interim Analysis of a Postmarketing Surveillance Study. [PDF]

Neurol Ther
Saito K, Saito T, Arakawa R, Takeshima Y, Nishio H, Ishikawa Y, Katsuno M, Tsumuraya T, Kawata H, Miyano Y, Komaki H.   +10 more
europepmc   +1 more source

Application of fungal communitiesfinger printings to determine the geographic origin of tropical timbers [PDF]

, 2010
Barbier, Georges, Henry, Renaud, Le Floch, Gaetan, Maurice, Sandy, Zaremski, Alba   +4 more
core  

Clinical Characteristics and Safety Profiles of Japanese Psoriasis Patients Who Continued Apremilast Treatment for 6 and 12 Months: A Post Hoc Analysis of an Apremilast Postmarketing Surveillance Study. [PDF]

J Dermatol
Ohtsuki M, Okubo Y, Saeki H, Igarashi A, Imafuku S, Abe M, Saito K, Ogawa R, Morita A.   +8 more
europepmc   +1 more source

DeepADR: multimodal prediction of adverse drug reaction frequency by integrating early-stage drug discovery information via Kolmogorov-Arnold networks. [PDF]

Brief Bioinform
Wan J, Jia C, Dong D, Chen Y, Lin YC, He Y, Huang HY, Huang HD.   +7 more
europepmc   +1 more source

FDA Approval Summary: Lisocabtagene Maraleucel for Relapsed or Refractory Follicular Lymphoma. [PDF]

Clin Cancer Res
Britton K, Mahat U, Richardson NC, Tegenge M, Gao Q, Theoret MR, Fashoyin-Aje LA.   +6 more
europepmc   +1 more source